v3.26.3
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total stockholders defici attributable to zeo [Member]
Noncontrolling Interest [Member]
Total
Beginning balance, value at Oct. 31, 2023 $ 7,000 $ 56,260,000 $ (57,508,000) $ (1,241,000) $ (1,241,000)
Beginning balance, shares at Oct. 31, 2023 7,283,483          
Sale of common stock 500,000 500,000 500,000
Sale of common stock, shares 250,000          
Reverse split round-up adjustment
Reverse split round-up adjustment, shares 5,803          
Cancellation of shares in connection with litigation $ (1,000) 1,000
Cancellation of shares in connection with litigation, shares (1,164,742)          
Purchase of shares in connection with litigation (80,000) (80,000) (80,000)
Purchase of shares in connection with litigation, shares (237,602)          
Exchange of accounts payable for stock 20,000 20,000 20,000
Exchange of accounts payable for stock, shares 20,000          
Fair value of equity instruments issued for compensation:            
Fair value of shares issued 450,000 450,000 450,000
Fair value of shares issued, shares 187,875          
Fair value of options issued 953,000 953,000 953,000
Fair value of warrants issued 2,450,000 2,450,000 2,450,000
Net (loss) income (4,705,000) (4,705,000) (4,705,000)
Ending balance, value at Oct. 31, 2024 $ 6,000 60,554,000 (62,213,000) (1,653,000) (1,653,000)
Ending balance, shares at Oct. 31, 2024 6,344,817          
Sale of common stock 300,000 300,000 300,000
Sale of common stock, shares 75,000          
Inducement expense to convert Notes payable 136,000 136,000 136,000
Conversion of Notes payable $ 1,000 513,000 514,000 514,000
Conversion of Notes payable, shares 171,347          
Acquisition of BioLumina 58,000 58,000 58,000
Acquisition of BioLumina, shares 30,000          
Exercise of warrants 50,000 50,000 50,000
Exercise of warrants, shares 21,277          
Fair value of equity instruments issued for compensation:            
Fair value of shares issued 233,000 233,000 233,000
Fair value of shares issued, shares 105,000          
Fair value of options issued 1,523,000 1,523,000 1,523,000
Fair value of warrants issued 2,937,000 2,937,000 2,937,000
Net (loss) income (5,521,000) (5,521,000) (5,521,000)
Ending balance, value at Oct. 31, 2025 $ 7,000 66,304,000 (67,734,000) (1,423,000) (1,423,000)
Ending balance, shares at Oct. 31, 2025 6,747,441          
Sale of common stock 2,150,000 2,150,000 2,150,000
Sale of common stock, shares 537,500          
Fair value of equity instruments issued for compensation:            
Fair value of shares issued $ 1,000 1,118,000 1,119,000 1,119,000
Fair value of shares issued, shares 552,500          
Fair value of options issued 3,596,000 3,596,000 3,596,000
Fair value of warrants issued 215,000 215,000 215,000
Net (loss) income (5,074,000) (5,074,000) 36,000 (5,038,000)
Ending balance, value at Jun. 30, 2026 $ 8,000 $ 73,383,000 $ (72,808,000) $ 583,000 $ 36,000 $ 619,000
Ending balance, shares at Jun. 30, 2026 7,837,441